Saxenda® (Liraglutide 3 mg) (NN8022)

:Filed for registration

A once-daily GLP-1 analogue for use as adjuvant to lifestyle changes intended to offer weight loss for people with severe obesity, including those at particular risk of developing diabetes. Approved in the US and under regulatory review in the EU.

Company announcements
Novo Nordisk receives positive opinion from the European regulatory authorities for Saxenda® (liraglutide 3 mg) for the treatment of obesity (22 Jan 2015)
Novo Nordisk receives FDA approval for Saxenda® for the treatment of obesity (23 Dec 2014)
Saxenda® for the treatment of obesity receives positive 14-1 vote in favour of approval from FDA Advisory Committee (11 Sep 2014)
Read more company announcements

Press releases
New phase 3a data demonstrate that 9 out of 10 adults with obesity lost weight with liraglutide 3 mg and clinical trial completers lost an average of 9.2% (04 Nov 2014)
Phase 3a liraglutide 3 mg trial demonstrated significant weight loss and improved cardiovascular risk factors in adults with obesity and type 2 diabetes compared with placebo (21 Jun 2014)
New phase 3a liraglutide 3 mg data showed positive impact on cardiovascular risk markers and fewer people progressing to prediabetes compared with placebo in adults with obesity (21 Jun 2014)
Read more press releases

Scientific abstracts
Diabetes (2007)
Diabetes Obesity and Metabolism (2008)
Diabetes Obesity and Metabolism (2008)
Read more scientific abstracts

You can search for more clinical trials on